This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| LAM Foundation | |
|---|---|
| Name | LAM Foundation |
| Formation | 1995 |
| Headquarters | Ann Arbor, Michigan |
| Type | Nonprofit organization |
| Purpose | Research, advocacy, patient support for lymphangioleiomyomatosis |
| Region served | International |
LAM Foundation
The LAM Foundation is a nonprofit organization focused on lymphangioleiomyomatosis, a rare lung disease affecting predominantly women, that advances research, funds clinical studies, and supports patients and families. Founded in 1995, the organization connects researchers, clinicians, pharmaceutical developers, and patient communities across North America, Europe, and Asia to accelerate therapies and improve outcomes. It operates collaborative programs, grant mechanisms, and advocacy initiatives that engage institutions such as the National Institutes of Health, European Respiratory Society, University of Michigan, and pharmaceutical companies including Novartis, Pfizer, and AstraZeneca.
The Foundation serves as a central hub linking patients, investigators, and sponsors in rare-disease ecosystems represented by entities like the National Organization for Rare Disorders, Global Genes, European Lung Foundation, American Thoracic Society, and patient registries associated with Johns Hopkins University and Mayo Clinic. It promotes translational projects that intersect with molecular biology centers such as the Broad Institute, Dana–Farber Cancer Institute, Fred Hutchinson Cancer Center, and the University of California, San Francisco clinical networks. The organization’s activities are guided by standards and guidelines from professional bodies including the World Health Organization and regulatory agencies like the U.S. Food and Drug Administration and the European Medicines Agency.
Founded by patient advocates and clinicians in 1995 following meetings with specialists from institutions such as Brigham and Women's Hospital, Cedars-Sinai Medical Center, and Yale School of Medicine, the Foundation rapidly established patient registries and seed-funding programs. Early collaborations involved investigators from Harvard Medical School, Stanford University School of Medicine, Columbia University Irving Medical Center, and Canadian centers like University of Toronto. Milestones include supporting pivotal translational studies that informed trials at centers including Massachusetts General Hospital, University of California, Los Angeles, and Mount Sinai Health System.
The Foundation’s mission emphasizes accelerating scientific discovery and providing community-centric support, aligning with philanthropic models exemplified by organizations such as the Bill & Melinda Gates Foundation and disease-specific groups like the Cystic Fibrosis Foundation and Pulmonary Fibrosis Foundation. Programs include patient education modeled after initiatives from American Lung Association, clinical trial navigation similar to Cancer Research UK platforms, and international outreach coordinated with networks like the European Reference Networks. Training and fellowship programs partner with academic centers including Imperial College London and Karolinska Institutet.
Grantmaking targets basic science, translational research, and clinical trials at institutions like University of Pennsylvania, Northwestern University, University of British Columbia, and Vanderbilt University Medical Center. The Foundation has funded projects in molecular pathways studied at the Salk Institute for Biological Studies, genetic research at the Wellcome Sanger Institute, and drug development efforts in collaboration with biotech hubs such as Cambridge Biomedical Campus and Mission Bay, San Francisco. It aligns grant review with advisory panels including experts from National Cancer Institute, European Molecular Biology Laboratory, and disease registries maintained by Johns Hopkins and University of Michigan.
Patient services mirror outreach models used by Susan G. Komen, Alzheimer's Association, and American Cancer Society through support groups, educational webinars featuring clinicians from UCLA Health, Duke University Health System, and Cleveland Clinic, and resource toolkits adapted for use alongside platforms like PatientsLikeMe. Advocacy work involves engagement with legislators and regulators including briefings with staff from the U.S. Congress and consultations with European Commission stakeholders to influence orphan-drug policies and access initiatives modeled after Orphanet collaborations.
The organization is governed by a board and scientific advisory committee with members from institutions such as University College London, National Heart, Lung, and Blood Institute, Scripps Research, and industry partners including Roche and GlaxoSmithKline. Strategic partnerships include alliances with registries and consortia like Respiratory Effectiveness Group, academic networks such as Translational Research Institute, and philanthropic collaborators resembling roles of Chan Zuckerberg Initiative in rare-disease funding.
Funding streams comprise individual philanthropy, grants, and industry-sponsored collaborations similar to mechanisms used by Howard Hughes Medical Institute-funded programs and corporate partnerships seen with Johnson & Johnson. Financial stewardship follows nonprofit transparency practices advocated by organizations like GuideStar and Charity Navigator, with budget allocations supporting research awards, patient programs, and administration across fiscal cycles reported to stakeholders including major donors and institutional partners.